Arcus Biosciences Announces New Employment Inducement Grants
13 Novembre 2023 - 10:35PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer, today
announced that the Compensation Committee of the Company’s Board of
Directors granted 12 new employees options to purchase a total of
31,200 shares of the Company’s common stock at an exercise price
per share of $16.01, which was the closing price on November 8,
2023, and restricted stock units to acquire a total of 15,600
shares of the Company’s common stock. The equity awards were
granted pursuant to the Company’s 2020 Inducement Plan, which was
approved by the Company’s Board of Directors in January 2020
pursuant to the “inducement exception” under NYSE Listed Company
Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
partners, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has advanced multiple investigational medicines into
clinical studies, including new combination approaches that target
TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and
HIF-2α. For more information about Arcus Biosciences’ clinical and
preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113078836/en/
Investor Inquiries: Pia Banerjee Head of Investor
Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com
Media Inquiries: Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Arcus Biosciences (NYSE:RCUS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024